Share on LinkedInShare on LinkedIn

ARTICLE · 05 SEPTEMBER 2022

Obviousness: Cannot Forget The Motivation To Combine Or Modify

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Tris asserted claims of all three patents against Actavis Laboratories FL, Inc. in the U.S. District Court for the District of Delaware.

United StatesIntellectual Property

Holding:

In Tris Pharma Inc. v. Actavis Laboratories FL, Inc., No. 21-1495 (Fed. Cir. July 7, 2022) (non-precedential), the Court of Appeals for the Federal Circuit ("Federal Circuit") affirmed the district court's holding that Actavis failed to show that the challenged claims would have been obvious.

Background:

Tris Pharma, Inc. ("Tris") owns U.S. Patent Nos. 8,465,765 ("the '765 patent"), 8,563,033 ("the '033 patent"), and 8,778,390 ("the '390 patent"), which have claims related to a liquid methylphenidate ("MPH") oral suspension with certain pharmacodynamic and pharmacokinetic properties. MPH is used to treat attention deficit hyperactivity disorder.

Tris asserted claims of all three patents against Actavis Laboratories FL, Inc. ("Actavis") in the U.S. District Court for the District of Delaware. The district court judge held that all asserted claims would have been obvious under 35 U.S.C. § 103. Tris Pharma, Inc. v. Actavis Lab'ys FL, Inc., 276 F.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from